全文获取类型
收费全文 | 49448篇 |
免费 | 3711篇 |
国内免费 | 203篇 |
专业分类
耳鼻咽喉 | 592篇 |
儿科学 | 1044篇 |
妇产科学 | 985篇 |
基础医学 | 6828篇 |
口腔科学 | 1158篇 |
临床医学 | 4895篇 |
内科学 | 10305篇 |
皮肤病学 | 1121篇 |
神经病学 | 4747篇 |
特种医学 | 2088篇 |
外国民族医学 | 2篇 |
外科学 | 8933篇 |
综合类 | 502篇 |
一般理论 | 78篇 |
预防医学 | 2762篇 |
眼科学 | 980篇 |
药学 | 2927篇 |
中国医学 | 88篇 |
肿瘤学 | 3327篇 |
出版年
2023年 | 425篇 |
2022年 | 877篇 |
2021年 | 1737篇 |
2020年 | 1025篇 |
2019年 | 1354篇 |
2018年 | 1561篇 |
2017年 | 1052篇 |
2016年 | 1235篇 |
2015年 | 1419篇 |
2014年 | 1906篇 |
2013年 | 2253篇 |
2012年 | 3648篇 |
2011年 | 3622篇 |
2010年 | 1999篇 |
2009年 | 1796篇 |
2008年 | 2852篇 |
2007年 | 2880篇 |
2006年 | 2684篇 |
2005年 | 2509篇 |
2004年 | 2322篇 |
2003年 | 2115篇 |
2002年 | 1945篇 |
2001年 | 626篇 |
2000年 | 590篇 |
1999年 | 608篇 |
1998年 | 447篇 |
1997年 | 358篇 |
1996年 | 266篇 |
1995年 | 260篇 |
1994年 | 218篇 |
1993年 | 221篇 |
1992年 | 395篇 |
1991年 | 373篇 |
1990年 | 338篇 |
1989年 | 308篇 |
1988年 | 285篇 |
1987年 | 278篇 |
1986年 | 264篇 |
1985年 | 295篇 |
1984年 | 232篇 |
1983年 | 227篇 |
1982年 | 186篇 |
1981年 | 167篇 |
1980年 | 175篇 |
1979年 | 199篇 |
1978年 | 164篇 |
1977年 | 150篇 |
1976年 | 145篇 |
1974年 | 148篇 |
1973年 | 131篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
Ian F. Dunn Pankaj K. Agarwalla Alexander M. Papanastassiou William E. Butler Edward R. Smith 《Child's nervous system》2007,23(10):1191-1194
Objective Approximately 10% of patients with neurofibromatosis I (NFI) patients will have central nervous system (CNS) tumors. The most
common of these are hypothalamic–optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas. While isolated
pilocytic astrocytomas in NFI are well described, the appearance of multiple pilocytic astrocytomas in an individual patient
is less common. The most frequent combination in NFI patients with more than one pilocytic astrocytoma is optic tract/hypothalamic
and brainstem. Other combinations are exceedingly rare; multiple pilocytic astrocytomas have only been reported once in the
cerebral hemispheres in a patient with NFI. This report presents the first documented case, to our knowledge, of multiple
pilocytic astrocytomas in the cerebellum of a patient with NF1.
Methods Case report.
Conclusion The finding of multiple cerebellar pilocytic astrocytomas in a patient with NF1 is important because it expands the spectrum
of presentations for patients with NF1 and also highlights specific diagnostic and therapeutic challenges faced by the treating
physicians. The genetic and molecular basis of NF1 is reviewed. Strategies of diagnosis and treatment outlined here are relevant
to both patients with NF1 and all patients with multiple posterior fossa tumors. 相似文献
63.
64.
Ohne Zusammenfassung 相似文献
65.
66.
Alexander Szarka 《Journal of molecular medicine (Berlin, Germany)》1939,18(26):914-915
Ohne Zusammenfassung 相似文献
67.
68.
Robert M. Levy Roman Saikovsky Evgeniya Shmidt Alexander Khokhlov Bruce P. Burnett 《Nutrition Research》2009
Flavocoxid (Limbrel), a proprietary mixture of flavonoid molecules (baicalin and catechin), was tested against a traditional nonsteroidal anti-inflammatory drug, naproxen, for the management of the signs and symptoms of moderate osteoarthritis (OA) in humans. Discomfort and global disease activity were used as the primary end points, and safety assessments were also taken for both treatments as a secondary endpoint. In this double-blind study, 103 subjects were randomly assigned to receive either flavocoxid [500 mg twice daily (BID)] or naproxen (500 mg BID) in a 1-month onset of action trial. Outcome measures included the short Western Ontario and McMaster University Osteoarthritis Index, subject Visual Analogue Scale for discomfort and global response, and investigator Visual Analogue Scale for global response and fecal occult blood. Both flavocoxid and naproxen showed significant reduction in the signs and symptoms of knee OA (P ≤ .001). There were no statistically detectable differences between the flavocoxid and naproxen groups with respect to any of the outcome variables. Similarly, there were no statistically detectable differences between the groups with respect to any adverse event, although there was a trend toward a higher incidence of edema and nonspecific musculoskeletal discomfort in the naproxen group. In this short-term pilot study, flavocoxid was as effective as naproxen in controlling the signs and symptoms of OA of the knee and would present a safe and effective option for those individuals on traditional nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 inhibitors. A low incidence of adverse events was reported for both groups. 相似文献
69.
70.